Serum Gasdermin B concentrations were significantly higher in bladder cancer patients compared to healthy controls, demonstrating moderate diagnostic value for differentiating the two groups.
Case-Control
No
Does serum Gasdermin B concentration have diagnostic value in differentiating patients with bladder cancer from healthy controls?
Serum GSDM B is significantly elevated in bladder cancer patients and shows moderate diagnostic value, suggesting potential utility as part of a multimarker diagnostic panel.
Bladder cancer (BC) is one of the most common urinary tract malignancies. In recent years, increasing attention has been paid to the role of pyroptosis—an inflammatory form of programmed cell death—in cancer development. Gasdermin B (GSDM B), a member of the gasdermin protein family, is involved in the regulation of inflammatory processes and the immune response, and its expression may be associated with cancer development and progression. The aim of the study was to assess GSDM B concentrations in the serum of patients with bladder cancer and to determine its potential diagnostic value in comparison with the tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). This study included patients with bladder cancer hospitalized at the Department of Urology, Medical University of Białystok, and a healthy control group. GSDM B concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA), while CEA and CA19-9 concentrations were determined by chemiluminescent microparticle immunoassay (CMIA). Concentrations in the serum of patients with bladder cancer were significantly higher than in the control group. A positive correlation was found between GSDM B and CEA and CA19-9 concentrations, as well as the age of the subjects. Receiver-operating characteristic (ROC) analysis demonstrated moderate but significant diagnostic value of GSDM B in differentiating patients with BC from healthy controls. No significant differences in GSDM B concentrations were observed between low- and high-grade tumors. These findings suggest that GSDM B may serve as a potential diagnostic marker for bladder cancer, particularly when used as part of a multimarker panel.
Pączek et al. (Thu,) conducted a case-control in Bladder cancer. Gasdermin B (GSDM B) concentration assessment vs. Healthy controls was evaluated on Diagnostic value of GSDM B in differentiating patients with bladder cancer from healthy controls. Serum Gasdermin B concentrations were significantly higher in bladder cancer patients compared to healthy controls, demonstrating moderate diagnostic value for differentiating the two groups.